Media
For media enquiries please contact:
media@evivebiotech.com
Latest Press Release
Evive Biotech Meets Primary and Secondary Endpoints in Global Phase III Clinical Trial for Their Novel Chemotherapy-induced Neutropenia Treatment
- 7 July 2020
Evive Successfully Concludes China Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia
- 6 January 2020
Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease
- 22 October 2019
Evive Announces Initiation of a Phase I Trial of A-319 to Treat Patients with B Cell Malignancies
- 9 September 2019
Evive Receives Investigative New Drug (IND) Approval from China SFDA for A-319 to Treat Patients with B Cell Malignancies
- 19 November 2018
Evive’s F-652 Shows Positive Results in “An Open Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy in Patients with Alcoholic Hepatitis”
- 19 November 2018
Evive Successfully Concludes First Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia and met primary endpoints
- 25 January 2018
China Patent Office Grants a Bi-Specific Antibody Patent to Evive
- 12 December 2017
Evive Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in Chemotherapy-induced Neutropenia
- 10 October 2017
